Dynamic dimerization

InNexus Biotechnology Inc. chose a well-validated target, CD20, to show that its second generation, conjugated monoclonal antibodies are more potent than first generation, unconjugated MAbs.

Last week, InNexus (TSX-V:IXS; IXSBF, Vancouver, B.C.) disclosed in vitro data showing that its DXL625 anti-CD20 MAb has greater

Read the full 441 word article

How to gain access

Continue reading with a
two-week free trial.